Cyclomide IV Infusion

Introduction

Cyclomide IV Infusion 200 mg/vial is a chemotherapy medication used to treat various cancers and some autoimmune diseases. It is classified as an alkylating agent, which works by interfering with the DNA replication of cancer cells, ultimately leading to cell death. It is also used in combination with other drugs to enhance its effectiveness in cancer treatment.

Uses

Cyclomide IV Infusion 200 mg/vial is used for:

Cancer Treatment: It is effective in treating several types of cancer, including leukemia, lymphoma, breast cancer, and ovarian cancer.
Autoimmune Diseases: It is used in managing severe autoimmune conditions such as systemic lupus erythematosus (SLE) and vasculitis.

The drug is often administered as part of a combination therapy to maximize its therapeutic effects and minimize resistance.

Brand Name	Cyclomide
Type	IV Infusion
Weight	200 mg/vial
Generic	Cyclophosphamide
Manufacturer	Techno Drugs Ltd.
Available in	English বাংলা

Mechanism of Action

Cyclomide IV Infusion 200 mg/vial acts as an alkylating agent that adds alkyl groups to DNA. This process cross-links DNA strands and prevents the DNA from uncoiling and separating, which is necessary for DNA replication and cell division. By interfering with DNA replication, Cyclomide IV Infusion 200 mg/vial induces cell death in rapidly dividing cells, such as cancer cells.

How Long Does It Take to Work?

The onset of action of Cyclomide IV Infusion 200 mg/vial depends on the condition being treated and the formulation used.

Cancer Treatment: Therapeutic effects can be observed within a few weeks, but significant improvement or response may take several weeks to months, depending on the type and stage of cancer.
Autoimmune Diseases: Initial improvement in symptoms may be seen within a few weeks, but full therapeutic effects may take longer to achieve.

Regular monitoring and follow-up are essential to assess response and adjust treatment as needed.

Absorption

Cyclomide IV Infusion 200 mg/vial is well-absorbed from the gastrointestinal tract when administered orally. It can also be given intravenously, where it is directly absorbed into the bloodstream. The absorption rate and extent may be influenced by factors such as the presence of food and the formulation used.

Route of Elimination

Cyclomide IV Infusion 200 mg/vial is primarily metabolized in the liver to active metabolites, including phosphoramide mustard. The drug and its metabolites are then excreted mainly through the urine. A small portion of the drug is also excreted in the feces.

Dosage

Treatment of Malignant Diseases: Adults and Children When used as the only oncolytic drug therapy, the initial course of cyclophosphamide for patients with no hematologic deficiency usually consists of 40 to 50 mg/kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly. Oral cyclophosphamide dosing is usually in the range of 1 to 5 mg/kg/day for both initial and maintenance dosing.

Many other regimens of intravenous and oral cyclophosphamide have been reported. Dosages must be adjusted in accord with evidence of antitumor activity and/or leukopenia. The total leukocyte count is a good, objective guide for regulating dosage. Transient decreases in the total white blood cell count to 2000 cells/mm³ (following short courses) or more persistent reduction to 3000 cells/mm³ (with continuing therapy) are tolerated without serious risk of infection if there is no marked granulocytopenia.

When cyclophosphamide is included in combined cytotoxic regimens, it may be necessary to reduce the dose of cyclophosphamide as well as that of the other drugs. Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used. Patients with compromised renal function may show some measurable changes in pharmacokinetic parameters of cyclophosphamide metabolism, but there is no consistent evidence indicating a need for cyclophosphamide dosage modification in patients with renal function impairment.

Treatment of Nonmalignant Diseases Biopsy Proven "Minimal Change" Nephrotic Syndrome in Children: An oral dose of 2.5 to 3 mg/kg daily for a period of 60 to 90 days is recommended. In males, the incidence of oligospermia and azoospermia increases if the duration of cyclophosphamide treatment exceeds 60 days. Treatment beyond 90 days increases the probability of sterility. Adrenocorticosteroid therapy may be tapered and discontinued during the course of cyclophosphamide therapy.

The dosage of Cyclomide IV Infusion 200 mg/vial varies depending on the condition being treated, the patient's response, and other factors:

Cancer Treatment: Dosages typically range from 1 to 5 mg/kg/day when given orally, or 500 to 1000 mg/m² when administered intravenously, depending on the specific cancer type and treatment protocol.
Autoimmune Diseases: Dosages may range from 1 to 2 mg/kg/day orally, or adjusted based on patient response and disease severity.

Dosage adjustments may be necessary based on tolerance and side effects. Regular monitoring of blood counts and organ function is essential during treatment.

Administration

Cyclomide IV Infusion 200 mg/vial can be administered orally or intravenously. For oral administration, it is usually taken with or without food, as directed by the healthcare provider. Intravenous administration is typically performed in a clinical setting under the supervision of a healthcare professional. Proper dosing and administration are crucial to minimize side effects and maximize efficacy.

Side Effects

Common side effects of Cyclomide IV Infusion 200 mg/vial include:

Nausea and vomiting
Bone marrow suppression (leading to low blood cell counts)
Hair loss
Fatigue
Increased risk of infections
Bladder irritation or hemorrhagic cystitis

Severe side effects can include severe infections, significant liver or kidney damage, and secondary malignancies. Immediate medical attention is required if severe reactions occur.

Toxicity

Toxicity with Cyclomide IV Infusion 200 mg/vial can manifest as severe bone marrow suppression, leading to neutropenia, anemia, and thrombocytopenia. Other severe toxic effects include hemorrhagic cystitis and possible long-term effects such as infertility or secondary cancers. Regular monitoring and supportive care are crucial to manage toxicity effectively.

Precautions

Precautions include:

Monitoring for signs of bone marrow suppression and adjusting dosage as needed.
Preventing bladder irritation by ensuring adequate hydration and using protective agents if required.
Regular liver and kidney function tests to monitor for potential organ damage.
Taking precautions against infections due to immunosuppression.

Inform the healthcare provider of any existing health conditions or concurrent medications to tailor the treatment plan accordingly.

Interaction

Cyclomide IV Infusion 200 mg/vial can interact with other medications, potentially altering its efficacy or increasing the risk of side effects. Interactions may occur with:

Other Chemotherapy Drugs: May increase the risk of adverse effects or toxicities.
Anticoagulants: May enhance the effects of blood thinners and increase bleeding risk.
Live Vaccines: Should be avoided due to potential interactions with the immune system.

Discuss all medications and supplements with the healthcare provider to manage interactions effectively.

Disease Interaction

Use Cyclomide IV Infusion 200 mg/vial with caution in patients with:

Existing infections, as the drug can suppress the immune system.
Pre-existing liver or kidney impairment, which can affect drug metabolism and excretion.
Bladder conditions or a history of bladder irritation, as the drug can exacerbate these issues.

Monitoring and dose adjustments may be necessary based on the individual’s health status.

Drug Interaction

Drug interactions can occur with:

CYP450 Enzyme Inhibitors: May alter the metabolism of Cyclomide IV Infusion 200 mg/vial, affecting its efficacy and side effects.
Other Immunosuppressants: Can increase the risk of infections and other immune-related issues.

Inform the healthcare provider of all concurrent medications to manage potential interactions.

Food Interactions

There are no specific food interactions with Cyclomide IV Infusion 200 mg/vial. However, taking the medication with food may help reduce gastrointestinal side effects. It is essential to follow dietary recommendations provided by the healthcare provider to avoid potential complications.

Pregnancy Use

Cyclomide IV Infusion 200 mg/vial is classified as a Category D drug for pregnancy, meaning there is evidence of risk to the fetus based on human studies. It should be used during pregnancy only if the potential benefit justifies the risk. Women of childbearing potential should use effective contraception during treatment.

Lactation Use

Cyclomide IV Infusion 200 mg/vial is excreted in breast milk, and its use during lactation is generally not recommended due to potential risks to the infant. Alternative feeding methods or discontinuation of breastfeeding may be advised during treatment. Consult a healthcare provider for guidance on lactation while on Cyclomide IV Infusion 200 mg/vial.

Acute Overdose

Acute overdose of Cyclomide IV Infusion 200 mg/vial can lead to severe toxicity, including significant bone marrow suppression and potential organ damage. Immediate medical attention is required, and management typically involves supportive care and symptomatic treatment to address the overdose effects.

Contraindication

Cyclomide IV Infusion 200 mg/vial is contraindicated in:

Patients with a known hypersensitivity to Cyclomide IV Infusion 200 mg/vial or any of its components.
Individuals with active infections or severe immunosuppression without adequate treatment.
Patients with severe hepatic or renal impairment where the drug may cause exacerbation of existing conditions.

Ensure that contraindications are reviewed before initiating treatment.

Use Direction

Follow the prescribed dosage and administration instructions carefully. For oral use, Cyclomide IV Infusion 200 mg/vial should be taken as directed, with or without food. Intravenous administration should be conducted under professional supervision. Adherence to the treatment plan and monitoring are essential for achieving optimal therapeutic outcomes.

Storage Conditions

Store Cyclomide IV Infusion 200 mg/vial at room temperature, away from moisture and direct sunlight. Keep it out of reach of children and handle with care due to its cytotoxic properties. Proper storage ensures the medication's stability and effectiveness.

Volume of Distribution

The volume of distribution for Cyclomide IV Infusion 200 mg/vial is not well-defined, but it is generally distributed throughout the body tissues, including the liver and kidneys, where it is metabolized. Its distribution can be affected by factors such as protein binding and tissue permeability.

Half Life

The half-life of Cyclomide IV Infusion 200 mg/vial varies depending on the administration route and individual patient factors. For intravenous administration, the elimination half-life ranges from approximately 3 to 12 hours. The oral half-life may be longer due to variable absorption and metabolism.

Clearance

Cyclomide IV Infusion 200 mg/vial is cleared from the body primarily through hepatic metabolism followed by renal excretion. The rate of clearance can be affected by liver and kidney function, with potential variations in individual patients. Monitoring of organ function is crucial to ensure proper drug clearance and minimize toxicity.

See in details version Cyclomide IV Infusion 200 mg/vial also Cyclomide IV Infusion 200 mg/vial in bangla